ASCO has released a Policy Statement for Use of Genetic Tests That Screens Multiple Cancer Genes. The American Society of Clinical Oncology (ASCO) has issued an updated policy statement on genetic and genomic testing for cancer susceptibility. Published in the Journal of Clinical Oncology, the statement reviews the ways in which new technologies are transforming the assessment and identification of inherited cancer susceptibility, and makes a series of recommendations for the optimal deployment of these technologies in oncology practice.
As cancer diagnosis and treatment is becoming more genetically-driven, new opportunities and questions are emerging about screening for hereditary cancers. ASCO Leadership Underscores Importance of Updated Policy Statement The “increase in genetic sequencing capability combined with the decrease in the cost of testing has altered both regulatory…
